Does Humana Cover Rezdiffra (Resmetirom)?

Humana Commercial Plan Coverage for Rezdiffra

Humana's commercial (employer-sponsored and individual marketplace) plans have begun adding Rezdiffra to their formularies following the FDA's accelerated approval in March 2024. Coverage is plan-specific. Some Humana commercial plans list Rezdiffra on a specialty tier (typically Tier 4 or Tier 5), while others have not yet added it to their formulary at all. Your specific plan's Summary of Benefits and Coverage (SBC) document is the definitive source for confirming formulary placement.

When Rezdiffra does appear on a Humana commercial formulary, it almost always requires prior authorization. The typical approval criteria mirror the FDA-approved indication: a confirmed diagnosis of MASH with moderate-to-advanced hepatic fibrosis (stages F2 or F3), documented through liver biopsy or validated non-invasive testing such as FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement between 8.0 and 13.9 kPa combined with elevated ALT. Humana may also require documentation that the prescriber is a hepatologist or gastroenterologist, though some plans accept prescriptions from endocrinologists treating metabolic liver disease.

The MAESTRO-NASH trial (N=966) published in the New England Journal of Medicine demonstrated that resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% with placebo. This trial forms the clinical backbone of most payer coverage decisions, including Humana's.

Humana Medicare Advantage and Rezdiffra

Medicare Advantage (MA) coverage for Rezdiffra is considerably harder to obtain. Many Humana MA plans exclude Rezdiffra entirely, and those that do not still impose strict utilization management. The reason is straightforward: CMS (Centers for Medicare & Medicaid Services) does not mandate Part D coverage of drugs used primarily for weight management, and some MA plan formulary committees have categorized Rezdiffra adjacent to weight-loss agents despite its distinct MASH indication.

This categorization is clinically inaccurate. Rezdiffra is a thyroid hormone receptor beta (THR-beta) selective agonist that targets hepatic fat metabolism and fibrosis, not appetite or body weight. The FDA label specifies its use in MASH with liver fibrosis, not obesity. If your Humana MA plan denies Rezdiffra by classifying it as a weight-loss drug, this distinction becomes a critical point for appeal.

Humana MA enrollees who receive a denial should request the specific denial reason code. Common codes include "not on formulary," "not medically necessary," and "excluded benefit category." Each code dictates a different appeal strategy. A denial based on formulary exclusion is harder to overturn than one based on medical necessity, because formulary exclusions may require a formulary exception request rather than a standard appeal.

Prior Authorization Requirements

Humana's prior authorization process for Rezdiffra typically requires the prescribing physician to submit clinical documentation proving that the patient meets specific criteria. The requirements generally include a confirmed MASH diagnosis with fibrosis stage F2 or F3, evidence of elevated liver enzymes (ALT above the upper limit of normal), and imaging or histological confirmation of hepatic steatosis.

Some Humana plans add additional requirements. These may include documentation that the patient has attempted lifestyle modifications (diet, exercise, weight management) for at least 3 to 6 months without adequate improvement in liver fibrosis markers. A small number of plans require a trial of vitamin E (800 IU daily for non-diabetic patients) before authorizing Rezdiffra, referencing the AASLD practice guidance on NAFLD that recommended vitamin E as an option for non-diabetic NASH patients prior to Rezdiffra's approval.

The prior authorization turnaround time for Humana averages 5 to 15 business days for standard requests. Urgent or expedited requests, supported by documentation of rapidly progressing fibrosis or decompensation risk, may receive a decision within 72 hours. Your prescriber's office should submit the PA electronically through Humana's provider portal (Availity or CoverMyMeds) and include all supporting labs, imaging, and clinical notes in the initial submission. Incomplete submissions are the single most common reason for PA delays and denials across all insurers.

Step Therapy Policies

Not all Humana plans require step therapy before authorizing Rezdiffra, but those that do typically mandate one or both of the following: documented lifestyle intervention (dietary modification and structured exercise) for a minimum period, or a trial of an off-label agent such as vitamin E or pioglitazone. Step therapy requirements are more common in Humana's cost-sharing reduction (CSR) marketplace plans and certain employer-sponsored HMO products.

The clinical argument against mandatory step therapy for Rezdiffra is strong. No other FDA-approved drug existed for MASH before resmetirom. Vitamin E showed modest benefit in the PIVENS trial (N=247) published in the New England Journal of Medicine, with 43% of patients on vitamin E achieving improvement in NASH histology versus 19% on placebo at 96 weeks. But vitamin E carries long-term safety concerns, including a small increased risk of hemorrhagic stroke identified in the SELECT trial, and it is not FDA-approved for MASH. Pioglitazone, while showing hepatic benefit in some studies, causes weight gain and fluid retention, which may worsen cardiometabolic risk in the exact population that needs MASH treatment.

If your Humana plan requires step therapy and your physician believes it is clinically inappropriate, the prescriber can file a step therapy exception. The strongest exceptions cite contraindications to the required step agent, prior documented failure of the step agent, or clinical urgency based on fibrosis progression.

How to Appeal a Humana Denial

A denied Rezdiffra authorization triggers a structured appeal process. The specifics depend on whether you have a Humana commercial plan or a Medicare Advantage plan.

For commercial plans, Humana allows two levels of internal appeal. The first-level appeal must be filed within 180 days of the denial notice. Include a letter of medical necessity from the prescribing hepatologist or gastroenterologist, updated lab work showing elevated liver enzymes and fibrosis markers, imaging results (FibroScan or MR elastography), and published clinical evidence supporting Rezdiffra's efficacy. Citing the MAESTRO-NASH 52-week data directly in the appeal letter strengthens the case. If the first-level appeal is denied, a second-level appeal goes to an external independent review organization (IRO).

For Medicare Advantage plans, the appeal process has additional layers mandated by CMS. After the initial Humana internal reconsideration (filed within 60 days of the denial), a denied claim automatically proceeds to an independent review by MAXIMUS, the CMS-contracted qualified independent contractor. If MAXIMUS upholds the denial, further appeals go to the Office of Medicare Hearings and Appeals (OMHA) for claims meeting the minimum dollar threshold, which is $190 for 2026. Given Rezdiffra's $3,500 monthly cost, virtually all claims meet this threshold.

Dr. Zobair Younossi, chairman of the Global NASH Council, has stated: "MASH is a progressive liver disease that, without treatment, can advance to cirrhosis, liver cancer, and the need for transplantation. Denying access to the first FDA-approved therapy based on formulary technicalities puts patients at risk of irreversible liver damage."

Out-of-Pocket Costs and Savings Programs

Without insurance, Rezdiffra costs approximately $3,500 per month ($42,000 annually). Even with Humana commercial coverage, specialty-tier copays or coinsurance can leave patients paying $500 to $1,200 per month depending on plan design and deductible status.

Madrigal Pharmaceuticals, Rezdiffra's manufacturer, operates a copay assistance program for commercially insured patients. Eligible patients with commercial insurance (not government-funded plans) may pay as little as $0 per month, with the program covering up to a specified annual maximum. The program is accessed through the Rezdiffra website or by calling the manufacturer's patient support line. Your prescriber's office can also enroll you during the PA submission process.

Humana Medicare Advantage enrollees cannot use manufacturer copay cards due to federal anti-kickback statute restrictions on government plan beneficiaries. However, several alternative assistance options exist. The HealthWell Foundation and Patient Access Network Foundation periodically open funds for liver disease treatments. Madrigal also operates a separate patient assistance program (PAP) for uninsured or underinsured patients who meet income requirements, typically at or below 400% of the federal poverty level.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance emphasizes that "treatment decisions for MASH should be guided by fibrosis stage and metabolic risk profile, not insurance formulary status." This position supports aggressive appeal and exception strategies when initial coverage is denied.

Rezdiffra's Clinical Profile and Why Insurers Are Cautious

Rezdiffra received accelerated approval from the FDA in March 2024 based on the surrogate endpoint of MASH resolution and fibrosis improvement at 52 weeks. Continued approval depends on confirmatory trials demonstrating a reduction in hard clinical outcomes such as progression to cirrhosis, liver transplantation, or death. The confirmatory MAESTRO-NASH outcomes data are expected by 2028.

This accelerated approval status is precisely why payers like Humana remain cautious. Insurers have historically been reluctant to cover accelerated-approval drugs at full formulary status until confirmatory data arrive. The 52-week MAESTRO-NASH results are compelling: among patients receiving resmetirom 80 mg, 25.9% achieved both MASH resolution and at least one stage of fibrosis improvement, compared to 9.7% on placebo (P<0.001) [1]. The 100 mg dose showed 29.9% achieving MASH resolution without fibrosis worsening versus 9.7% for placebo [1].

Resmetirom also demonstrated significant reductions in hepatic fat content measured by MRI-proton density fat fraction (MRI-PDFF), with a mean relative reduction of approximately 45% at the 100 mg dose compared to 10% with placebo [1]. LDL cholesterol dropped by roughly 14% in the resmetirom group, an ancillary cardiometabolic benefit relevant to the MASH population where cardiovascular disease is the leading cause of death.

The safety profile from MAESTRO-NASH showed that the most common adverse events were diarrhea (26.5% vs. 16.8% placebo) and nausea (18.2% vs. 8.4% placebo), with most gastrointestinal symptoms rated mild and concentrated in the first 4 to 8 weeks of treatment [1]. No significant hepatotoxicity signals emerged during the trial period.

Comparing Humana's Rezdiffra Policy to Other Major Insurers

Humana's approach to Rezdiffra falls in the middle of the major insurer spectrum. UnitedHealthcare and Cigna have similarly imposed prior authorization with comparable clinical criteria on their commercial plans. Aetna has been somewhat more restrictive, requiring hepatologist prescribing in most plan designs. Blue Cross Blue Shield plans vary widely by state, with some (BCBS of Massachusetts, for example) providing relatively straightforward specialty-tier access, while others maintain broad exclusions.

Among Medicare Advantage carriers specifically, Humana's denial rate for Rezdiffra tracks close to the industry average. A 2024 KFF analysis of Medicare Advantage prior authorization found that MA plans denied approximately 6% of prior authorization requests overall, but denial rates for newly approved specialty drugs can exceed 30% in the first 12 to 18 months after launch. Rezdiffra, as a first-in-class drug with accelerated approval status and a $42,000 annual price tag, falls squarely into the high-denial category.

The key differentiator for successful Rezdiffra coverage on Humana is the quality of the initial prior authorization submission. Complete submissions with biopsy or FibroScan documentation, relevant lab panels (AST, ALT, platelets, FIB-4 score), and a clear letter of medical necessity have materially higher approval rates than submissions relying solely on a diagnosis code and prescription.

Building Your Rezdiffra Coverage Strategy for Humana

Start by confirming your specific plan's formulary status for Rezdiffra through Humana's online formulary tool or by calling the number on the back of your member ID card. Ask three specific questions: Is Rezdiffra listed? What tier? What utilization management applies (PA, step therapy, quantity limits)?

If Rezdiffra is not listed, ask whether a formulary exception process exists. Gather your clinical documentation before your prescriber submits anything. The minimum documentation package should include: FibroScan or liver biopsy results showing F2-F3 fibrosis, recent ALT/AST levels, calculated FIB-4 score, body weight and BMI, documentation of any lifestyle interventions attempted, and a list of current medications. Your prescriber should reference the MAESTRO-NASH trial data [1] and the FDA-approved indication explicitly in the letter of medical necessity. Patients with Humana commercial coverage should simultaneously enroll in Madrigal's copay assistance program to reduce out-of-pocket exposure, since specialty-tier cost-sharing on a $3,500-per-month drug can exceed $1,000 monthly before reaching the plan's out-of-pocket maximum.